Glycopyrrolate topical - Dermira

Drug Profile

Glycopyrrolate topical - Dermira

Alternative Names: DRM-04B; DRM04; Glycopyrronium tosylate; Glycopyrronium tosylate hydrate; Glycopyrronium tosylate monohydrate

Latest Information Update: 07 Apr 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Stiefel Laboratories
  • Developer Dermira
  • Class Antiasthmatics; Antispasmodics; Pyrrolidines; Quaternary ammonium compounds; Skin disorder therapies; Small molecules
  • Mechanism of Action Muscarinic receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase III Hyperhidrosis

Most Recent Events

  • 03 Mar 2017 Efficacy data from the phase III ATMOS-1 and ATMOS-2 trial presented at 75th Annual Meeting of the American Academy of Dermatology (AAD)
  • 28 Feb 2017 Dermira announces intention to submit NDA to the US FDA in 2H 2017
  • 01 Dec 2016 Dermira completes the long-term phase III safety trial in Hyperhidrosis in USA and Germany (NCT02553798)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top